Telesis Bio (NASDAQ:TBIO) Shares Down 9.5% – Here’s Why

Telesis Bio, Inc. (NASDAQ:TBIO) fell 9.5% during trading on Wednesday . The stock traded as low as $0.38 and last traded at $0.38. 3,856 shares were traded during trading, a decline of 99% from the average session volume of 410,007 shares. The stock had previously closed at $0.42.

Telesis Bio Stock Performance

The business has a fifty day moving average of $0.97 and a two-hundred day moving average of $2.59. The firm has a market capitalization of $785,880.00, a price-to-earnings ratio of -0.02 and a beta of 1.59.

Telesis Bio (NASDAQ:TBIO) last released its quarterly earnings data on Thursday, November 7th. The company reported ($3.83) EPS for the quarter. The company had revenue of $1.57 million during the quarter. Telesis Bio had a negative net margin of 336.59% and a negative return on equity of 359.32%.

About Telesis Bio

Telesis Bio, Inc, a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. The company offers BioXp 3250 system and BioXp 9600 system that empower researchers to go from a digital DNA sequence to endpoint-ready synthetic deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA) with onboard next generation sequencing (NGS) library preparation; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice, as well as mRNA constructs; and BioXp De Novo kits, which contains building blocks and reagents, including proprietary Gibson assembly branded reagents for specific synthetic biology workflow applications.